Lincosa Injection 300mg - 10ml

Manufacturer
L.B.S. Labs Ltd.

Registraction Number     
MAL18046256A

 

 

Content

• Active Ingredient: Each 10 mL vial contains 300 mg of lincomycin hydrochloride, equivalent to 30 mg/mL of lincomycin.
• Formulation: Sterile solution for injection, intended for intravenous (IV), intramuscular (IM), or subconjunctival administration.
• Preservative: Contains benzyl alcohol as a preservative, which may pose risks in neonates and infants.

Indications

• Severe Infections: Indicated for the treatment of serious infections caused by susceptible strains of bacteria, including:
  • Streptococci
  • Pneumococci
  • Staphylococci
• Penicillin-Allergic Patients: Reserved for use in patients who are allergic to penicillin or for whom penicillin is inappropriate.
• Surgical Infections: May be used in conjunction with surgical procedures to treat or prevent infections.

Instructions

• Administration: Administered by healthcare professionals via:
  • Slow intravenous infusion over at least 60 minutes.
  • Intramuscular injection.
  • Subconjunctival injection for ocular infections.
• Dosage:
  • Adults:
    • Intravenous (IV): 600 mg every 8–12 hours.
    • Intramuscular (IM): 600 mg every 12–24 hours.
  • Maximum Daily Dose: Do not exceed 8 grams per day.
  • Children:
    • IV/IM: 10 mg/kg every 12–24 hours.
    • IV: 3.3–6.7 mg/kg every 8 hours or 5–10 mg/kg every 12 hours.
• Storage: Store under conditions specified on the packaging, away from children and pets.
• Precautions:
  • Monitor for signs of Clostridium difficile-associated diarrhea (CDAD), which can occur during or after treatment.
  • Use with caution in patients with a history of gastrointestinal disease, particularly colitis.
  • Monitor liver and kidney function during prolonged therapy.
  • Avoid concurrent use with erythromycin due to potential antagonistic effects.